Differential Selectivity of Human and Mouse ABCC4/Abcc4 for Arsenic Metabolites

Brayden D Whitlock1, Yingze Ma1, Gwenaëlle Conseil1

  • 1Department of Physiology (B.D.W., Y.M., A.R.O., M.B., D.P.S., E.M.L.), Membrane Protein Disease Research Group (B.D.W., Y.M., M.B., D.P.S., E.M.L.), and Division of Analytical and Environmental Toxicology, Department of Laboratory Medicine and Pathology (X.C.L., E.M.L.), University of Alberta, Edmonton, Alberta, Canada; Department of Pathology and Molecular Medicine, Division of Cancer Biology and Genetics, Sinclair Cancer Research Institute, Queen's University, Kingston, Ontario, Canada (G.C., S.P.C.C.); Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut (Z.P.L.); and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee (Y.W., J.D.S.).

Insights

Mouse Abcc4 (mABCC4) does not transport arsenic species, unlike its human counterpart (hABCC4). This difference in transporter function likely explains why arsenic is a poor carcinogen in rodents compared to humans.

Area of Science:

  • Environmental Health
  • Toxicology
  • Molecular Biology

Background:

  • Millions worldwide are exposed to arsenic in drinking water, a known human carcinogen.
  • Rodents are less susceptible to arsenic carcinogenicity, suggesting species-specific toxicokinetic differences.
  • The human transporter hABCC4 plays a role in excreting toxic arsenic metabolites.

Purpose of the Study:

  • To investigate if mouse Abcc4 (mAbcc4) transports arsenic species similarly to hABCC4.
  • To determine if mAbcc4 confers resistance to arsenic compounds in cells.
  • To understand the role of mAbcc4 in species-specific arsenic toxicokinetics.

Main Methods:

  • Epitope mapping of the anti-ABCC4 antibody M4I-10 to quantify hABCC4 and mAbcc4 levels.
  • Expression of mAbcc4 in HEK293 cells to test for arsenic resistance and transport.
  • Preparation of membrane vesicles from transfected cells to assess transport activity.
  • Comparison of arsenate resistance in wild-type and Abcc4-knockout mouse embryonic fibroblasts.

Main Results:

  • mAbcc4 did not protect against any tested arsenic species in HEK293 cells.
  • mAbcc4 did not transport key arsenic metabolites MMA(GS)2 and DMA(V).
  • While Abcc4(+/+) MEFs showed slight resistance to arsenate, it was not mediated by mAbcc4.

Conclusions:

  • Arsenicals are not substrates for mAbcc4 under the tested conditions.
  • Significant differences exist in the substrate selectivity between hABCC4 and mAbcc4.
  • Divergent transporter functions likely contribute to the observed differences in arsenic toxicokinetics between humans and mice.

Related Concept Videos

Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
44
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
125
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
34
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.5K